Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
2 sources·Updated September 8, 2026
Covered by 2 sources
- ET Markets·11h agoBiocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal
Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development comes alongside Biocon’s Brazil partnership for Pertuzumab under a 10-year programme.
Read at ET Markets → - Economic Times·20h agoBiocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.
Read at Economic Times →
